ArticleExperimental and therapeutic medicine2025
Efficacy of Tirofiban combined with oral antiplatelet therapy in progressive ischemic stroke: A systematic review and meta-analysis.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-tumor effects and immuno-inflammatory-metabolic mechanisms of Buzhong Yiqi Granules in improving cancer-related fatigue in lung cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This meta-analysis aimed to evaluate the safety and efficacy of combining tirofiban with oral antiplatelet agents in treating patients with progressive ischemic stroke. The investigators searched several databases, including PubMed, Web of Science, the Cochrane Library, CNKI, VIP, WanFang Data and Sinomed. The search was restricted to literature published before May 5, 2025, without any language restrictions. Stata software 17.0 was used to analyze the results and assess risk of bias. A total of 19 studies comprising 3,667 patients were included in the analysis. Furthermore, statistically significant differences (P<0.05) were observed when comparing the tirofiban group and the control group regarding the incidence of achieving a 3-month modified Rankin scale (mRS) score of 0-2, the National Institutes of Health Stroke Scale score, the mRS score, activities of daily living, the platelet aggregation rate, the platelet adhesion rate and the effective rate. However, no significant differences (P>0.05) were detected in the risks of intracranial hemorrhage, other systemic hemorrhage, mortality rate and serious adverse events between the two groups. The study was conducted according to the preferred reporting items for systematic reviews and meta-analyses guidelines and registered with PROSPERO (no. CRD42025633357), and the findings suggested that tirofiban-augmented antiplatelet regimens safely improve clinical outcomes in progressive cerebral infarction, particularly when combined with dual oral antiplatelet agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.